Three Years After Legalization, Canada Has Little Information About How It Changed Cannabis Use and Health Harms

In an editorial piece penned by Public Health Physician and Canadian Institutes of Health Research Fellow Daniel Myran for The Conversation, Dr. Myran explains the lack of timely and current data on recreational cannabis legalization before a mandated review of the health impacts.

He cites three main areas that limit the understanding of legalization’s health impact. First, almost all studies to date examining the impact of legalization on cannabis use and harms have only looked at changes during the first year following legalization. Second, many types of cannabis products, including commercially produced edibles such as THC-containing candies, desserts and drinks, only became available for sale in January 2020. Last, over half of the time since legalization has been during the pandemic. There is no easy way to separate the effects of the pandemic versus a maturing cannabis market on the recent increases in cannabis use.

To read the full story, click here: https://theconversation.com/3-years-after-legalization-we-have-shockingly-little-information-about-how-it-changed-cannabis-use-and-health-harms-169815

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

IASIC Speaker Series Presents  Cannabis and Mental Health

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Placebo Effect a Major Driver of Pain Reduction in Cannabis Trials

A strong placebo response may be largely responsible for the significant pain reduction observed in clinical trials of cannabis-based therapies, results of a new meta-analysis suggest. Investigators found that while the effect size of cannabinoids on pain intensity was significant, the placebo effect was about the same. “The data from the present meta-analysis, including 1459

Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005–2019

Since 2005, diagnoses of cannabis use disorder have increased substantially among VHA patients, as they have in the general population and other patient populations. Possible explanations warranting investigation include decreasing perception of risk, changing laws, increasing cannabis potency, stressors related to growing socioeconomic inequality, and use of cannabis to self-treat pain. Clinicians and the public

Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado

The primary objective of this study was to evaluate the association between presence of recreational cannabis dispensaries and prevalence of cannabis-involved pregnancy hospitalizations in Colorado. This was a retrospective cohort study of pregnancy-related hospitalizations co-coded with cannabis diagnosis codes in the Colorado Hospital Association from January 1, 2011, through December 31, 2018 (recreational cannabis began

Scroll to Top